Clinical Trials Logo

Clinical Trial Summary

The goal of this intervention study is to compare the adaptations after a 6-week training period between an intense continuous and a high-intensity interval training program performed under iso-effort conditions on aerobic performance parameters in young healthy adults. The main question it aims to answer are if the intense continuous and a high-intensity interval training programs will induce similar adaptations in maximal (VO2max and PTV) and submaximal (critical velocity, lactate threshold parameters and running economy) aerobic performance parameters. Participants will be ere randomly assigned either to an intense continuous training group (CON) or to a high-intensity interval training group (INT). The training program will comprise of 14 training sessions performed over a 6-week period.


Clinical Trial Description

The aim of this study was to compare the adaptations after a 6-week training period between the intense continuous and the high-intensity interval training methods performed under iso-effort conditions on maximal (VO2max and PTV) and submaximal (critical velocity, lactate threshold parameters and running economy) aerobic performance parameters. A parallel group research design was used in the present study. Initially, 26 participants (10 males and 16 females), using stratified randomization (gender was the variable of stratification) were randomly assigned (1:1), according to a random-number table, either to an intense continuous training group (CON) or to a high-intensity interval training group (INT). The INT group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the "new" PTV achieved during mid-testing as a result of training. The CONT group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains. During the experiment, participants will not perform any other form of training besides of that applied in the current study. VO2max, PTV, oxygen consumptions, heart rates and the velocities corresponding to the 1st and the 2nd lactate thresholds (LT1 and LT2), the velocity at 4 mmol/L of blood lactate concentration (v4mmol), running economy, and critical velocity (CV) will be measured before, after 7 training sessions (3rd week, two days after the 7th training session), and after the completion of training program. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05729685
Study type Interventional
Source Democritus University of Thrace
Contact
Status Completed
Phase N/A
Start date September 1, 2020
Completion date December 10, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1